Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
Authors
Keywords
Breast cancer, Disease-free survival, Overall survival, Cytotoxic T lymphocyte antigen 4, CTLA-4
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 7, Pages 853-860
Publisher
Springer Nature
Online
2015-04-16
DOI
10.1007/s00262-015-1696-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer
- (2014) Hai-ming Yu et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Ipilimumab in the treatment of metastatic melanoma: management of adverse events
- (2014) Giuseppina Della Vittoria Scarpati et al. OncoTargets and Therapy
- The soluble isoform of CTLA-4 as a regulator of T-cell responses
- (2013) Frank J. Ward et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription
- (2013) Arianne Pérez-García et al. HUMAN IMMUNOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Mammaglobin-A Immunohistochemistry in Primary Central Nervous System Neoplasms and Intracranial Metastatic Breast Carcinoma
- (2013) Patrick J. Cimino et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor β2
- (2012) Meghan A. Koch et al. IMMUNITY
- Basic Science for the Clinician 55
- (2012) Leonard H. Sigal JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer
- (2010) Nasrollah Erfani et al. CANCER INVESTIGATION
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- New Insights of CTLA-4 into Its Biological Function in Breast Cancer
- (2010) H. Mao et al. CURRENT CANCER DRUG TARGETS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased CTLA-4 and FOXP3 Transcripts in Peripheral Blood Mononuclear Cells of Patients with Breast Cancer
- (2010) Mansooreh Jaberipour et al. PATHOLOGY & ONCOLOGY RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started